Loading clinical trials...
Loading clinical trials...
A Phase 2b, Open-label, Multicenter, Randomized Parallel-Group, Two-Stage, Study of an Immunotherapeutic Treatment DPX-Survivac and Pembrolizumab, With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (VITALIZE)
Conditions
Interventions
DPX-Survivac
Pembrolizumab
+1 more
Locations
50
United States
Compassionate Cancer Care Medical Group
Fountain Valley, California, United States
Boca Raton Regional Hospital
Boca Raton, Florida, United States
BRCR Medical Center Inc.
Hollywood, Florida, United States
BRCR Medical Center Inc.
Plantation, Florida, United States
Comprehensive Hematology and Oncology
St. Petersburg, Florida, United States
Blood and Marrow Transplant Group of Georgia
Atlanta, Georgia, United States
Start Date
June 18, 2021
Primary Completion Date
October 1, 2024
Completion Date
April 1, 2025
Last Updated
April 7, 2023
NCT05755087
NCT05672251
NCT06905509
NCT06859008
NCT05052528
NCT01959698
Lead Sponsor
ImmunoVaccine Technologies, Inc. (IMV Inc.)
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions